UNASSIGNED: 4097 Background: The clinical relevance of genomic imbalances in @entity788 is uncertain. The aim of this study was to evaluate whether alterations in specific genes influenced clinical outcome in resected @entity788 @entity1 . METHODS: Recurrent copy number alterations of cytobands and genes were analyzed by array comparative genomic hybridization (aCGH) in 44 resected @entity788 specimens from a Korean cohort, including 24 @entity1 who received adjuvant chemotherapy regimens with @entity136 or @entity1487 . Statistical analysis enabled us to assess the interaction of copy number alterations with clinicopathological variables and @entity1349 ( @entity1349 ). Prognostic markers identified by aCGH were validated by PCR gene copy number assay in an independent Italian cohort of 61 resected pT3N1Mx stage @entity788 treated with @entity136 adjuvant therapy. RESULTS: Recurrent copy number gains were observed in chromosome 1q, 11q, 18q11.1-11.2, and 20q13.13; and losses in chromosome 2p, 9p, 10q, 14q, 15q, 18q12.2-23, 19q, 20q11.1, 21p, and 22q. Loss of cytoband 18q22.3 (in 8 @entity1 ) was significantly more frequent in @entity1 surviving shorter than the median @entity1349 (p=0.021, @entity16043 -Exact test). This cytoband encodes 5 genes, including @entity18086 , whose copy number was associated with @entity1349 (p=0.019, log-rank test). The copy number of this gene was subsequently assessed in the Italian cohort, where @entity1 with deletion (N=41) had shorter @entity1349 (p=0.003, log-rank test). Multivariate analysis of the two cohorts showed that loss/deletion of 18q22.3/ @entity18086 was an independent poor prognostic factor for @entity1349 (hazard ratio 2.72, p=0.0007) after adjusting for other factors influencing clinical outcome. CONCLUSIONS: Through aCGH analysis, we identified loss/deletion of 18q22.3/ @entity18086 as a potentialindependent poor prognostic factor in resected @entity788 . Given the heterogeneity of the two cohorts, further confirmation on a large number of @entity1 is warranted. However, the combined Cox model suggests that this @entity74 may have a meaningful impact on @entity1349 of @entity788 @entity1 , and its biological implications are being investigated.

Array-based comparative genomic hybridization analysis to identify prognostic markers for resected XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'pancreatic cancers'] @entity18086 :: ('55748', 'Gene') :: ['CNDP2'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic alteration'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity16043 :: ('76720', 'Species') :: ['Fisher'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
